Given that the industry has hundreds of billions of dollars invested in plants that do batch manufacturing, it has been hard for the industry to commit to a new way of making drugs, even one with the potential to cut costs dramatically. But at a major conference in May, the industry coalesced around the need to adopt continuous manufacturing.
If 2014 was the year of the emboldened U.S. payer, then 2015 promises to be the year of the pharma negotiator.
Bayer, which picked up Merck's consumer health unit in a $14.2 billion deal this spring, wanted to fold in all the brands from the New Jersey pharma giant's lineup. But to do so, it had to do some creative assignment shuffling. And its agencies had to take some creative steps of their own.
As surely as Linus and Lucy's jazz theme plays in shops decorated with Santa's and garland, and blue-and-white-wrapped chocolates and menorah candles appear on store shelves; as surely as calendar pages flutter into the trash, FiercePharma peers into the murky future to predict which headlines we'll be writing next year.
Restructuring is an all-purpose word. It can be a euphemism for layoffs. It can mean a quick redraw of the corporate organizational chart. It can cover big shifts in management responsibilities and operations. It can handle even bigger moves, like AstraZeneca's headquarters shift, R&D overhaul, and worldwide job cuts. And then there's restructuring with a capital R.
It has been a whirlwind of a year for pharma, with pricing battles, regulatory showdowns and all-but-legendary M&A. And on the ground, it's Rock-em-Sock-em Robots in some of the industry's biggest markets. A steady flow of new drugs in 2014--and a slate of anticipated launches in 2015--have established brands defending their titles and newcomers looking to land a gut-punch or two, if not a knockout.
It's been a wild ride through the M&A world for pharma this year, and analysts predict that may just continue into 2015. Companies have been wheeling and dealing at breakneck pace, with more than a couple inking multiple pacts. But plenty of drugmakers are still in search of a deal that will move the needle.
No luck for Sanofi in turning over a Plavix antitrust fine. A Paris appeals court has upheld the €40.6 million ($49.7 million) penalty for trying to keep doctors and pharmacists from prescribing or subbing copycat versions of the former blockbuster blood thinner, Law360 reports.
Once again, long-term care pharmacy Omnicare is at the center of a Department of Justice kickback probe. This time, the drugmaker in focus is Abbott Laboratories. The drug, Depakote.
Express Scripts may have warned the world that it would use its gatekeeper status to force big hepatitis C discounts. But when word of its exclusive, discounted deal with AbbVie actually hit on Monday, analysts went a-Twitter, biotech shares slid, other payers pricked up their ears--and media outlets went berserk.
Bristol-Myers scored FDA approval for its cancer immunotherapy Opdivo (nivolumab) three months ahead of schedule, setting it up for a head-to-head contest against Merck's recent debut in the same class, Keytruda.
With J.P. Morgan analysts predicting the biopharma sector can take its hot streak into 2015, they've ID'd companies ranging from tiny BioMarin to whopper Bristol-Myers Squibb that should stand out from the crowd.
Nonpublic information about Abbott's May agreement to buy CFR Pharmaceuticals helped score a former CFR board member a hefty profit, according to U.S. regulators. And they're charging him with insider trading.
Pharma companies are turning to experienced professionals to field questions from consumers at call centers, according to a new survey from Cutting Edge Information.
Merck's $9.5 Cubist buyout got off to a rocky start when a U.S. court nixed all but one patent covering top-seller Cubicin. And now, it'll be up to brand-new FDA approval Zerbaxa to turn things around.
AstraZeneca won accelerated FDA approval for its ovarian cancer fighter Lynparza (olaparib), opening the door for potential blockbuster sales of the drug and helping the company distinguish itself from rivals in the BRCA playing field.
In one interview published over the weekend, AstraZeneca CEO Pascal Soriot pooh-poohed the idea of Pfizer coming back with another takeover bid. In another, he gave a subtle warning about his company's stated goal of hitting $45 billion in sales within a decade.
With Friday's approval of all-oral hep C regimen Viekira Pak, AbbVie's got a future blockbuster on its hands. And it couldn't have arrived soon enough.
AbbVie has made Express Scripts' wish come true. Or perhaps it's the other way around. The proud new parent of Viekira, a highly anticipated hepatitis C cocktail, AbbVie now has exclusive access to millions of the pharmacy benefits manager's patients in return for a "significant discount" off its $85,000 list price.
Just one month after announcing a $66 billion pact to buy Allergan, Actavis is eyeing Spain's Almirall as a way to boost its European growth, according to Bloomberg.